Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report

Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report

Jacques F. Meis, Jochem B. Buil, Eelco F. J. Meijer, Anton S. M. Dofferhoff, Oscar Hoiting

COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agents puts emphasis on early surveillance for azole-resistant Aspergillus species. We present a patient with putative CAPA due to Aspergillus fumigatus with identification of a triazole-resistant isolate during therapy. We underline the challenges faced in the management of these cases, the importance of early diagnosis and need for surveillance given the emergence of triazole resistance.

2020

co-infection, Pulmonary aspergillosis, ICU, <i>Aspergillus fumigatus</i>, SARS-CoV-2, azole-resistant <i>Aspergillus</i>

DOI: 10.3390/jof6020079

Journal of Fungi

MDPI AG

Biology (General)